Clinical impact of first-line chemotherapy combined with immune checkpoint inhibitors for limited-stage small cell lung cancer patients: a real-world propensity score matching study
These results offer reliable references for clinicians when formulating treatment strategies for LS-SCLC patients and also provide support for future clinical trials.
Authors
- Huina Wang
- Quanman Hu (ORCID: https://orcid.org/0000-0003-4250-9713)
- Boying Wu
- Fei Zhao (ORCID: https://orcid.org/0009-0008-6335-4777)
- Chenyi Zhou (ORCID: https://orcid.org/0009-0008-5359-8196)
- Shuaiyin Chen
- Xiyin Wang
- Xiaoru Song
- Yuan Ding
- Bin Jia
Institutions
- Zhengzhou University (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-21
- DOI
- https://doi.org/10.3389/fimmu.2026.1731123
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wu Jieping Medical Foundation